Ongoing Efforts to Open Additional Clinical Sites for Recruitment at Premier Cancer Centers Across the U.S. and Europe
Facilitating Patient Enrollment and Dosing for Pancreatic Cancer Treatment Study
OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)
AIM ImmunoTech Inc. has recently announced the launch of a Phase 2 study of Ampligen® for the treatment of pancreatic cancer. This study is currently open and actively recruiting patients at premier cancer centers across the United States and Europe. The company is focused on advancing research and development in the field of immuno-pharma to provide innovative treatment options for cancer patients.
Pancreatic cancer is a devastating disease with limited treatment options and a high mortality rate. AIM ImmunoTech is dedicated to exploring the potential of Ampligen® as a targeted therapy for pancreatic cancer, offering hope to patients who are in need of effective treatments.
By opening additional clinical sites for recruitment, AIM ImmunoTech aims to accelerate patient enrollment and dosing for this important study. The company is committed to advancing the development of Ampligen® and bringing new treatment options to patients with pancreatic cancer.
Patients who are interested in participating in the Phase 2 study of Ampligen® for pancreatic cancer treatment are encouraged to contact their healthcare provider or visit the AIM ImmunoTech website for more information on how to enroll in the study.
How This Will Affect Me
If you or a loved one is currently battling pancreatic cancer, the Phase 2 study of Ampligen® offered by AIM ImmunoTech may provide a new treatment option that could potentially improve outcomes and quality of life. Participation in clinical trials like this one can open up access to cutting-edge therapies and resources that may not be available through standard treatment options.
How This Will Affect the World
The development of new therapies for pancreatic cancer, such as Ampligen®, has the potential to revolutionize the way this deadly disease is treated on a global scale. By conducting clinical trials at premier cancer centers across the U.S. and Europe, AIM ImmunoTech is paving the way for innovative treatments that could benefit patients worldwide. The results of this study have the potential to make a significant impact on pancreatic cancer treatment and improve outcomes for patients everywhere.
Conclusion
The ongoing Phase 2 study of Ampligen® for the treatment of pancreatic cancer represents a major step forward in the fight against this devastating disease. By opening additional clinical sites for recruitment and actively enrolling patients, AIM ImmunoTech is working tirelessly to bring new hope and treatment options to those in need. With advancements like this, the future of pancreatic cancer treatment looks brighter than ever.
